palliative care group first-line scheme
ApprovedSmall molecule
palliative care group first-line scheme is one of 35 small molecule programs targeting Colorectal Cancer. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1palliative care group first-line scheme
GGuang'anmen Hospital of China Academy of Chinese Medical Sciences
Approved
Eylea
RegeneronPreclinical
PORTRAZZA
Eli LillyPreclinical
Emend IV
Merck & Co.Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Gas-X
PPortuguese Oncology Institute, Coimbra
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Colorectal Cancer1 trial
Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer
Recruiting·GGuang'anmen Hospital of China Academy of Chinese Medical Sciences·Phase 4·NCT05894694·320 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details